Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AEterna Zentaris Inc Announces Preclinical Data For Aezs-108 In Bladder Cancer Published Online In Oncotarget


Thursday, 26 Jul 2012 07:37am EDT 

AEterna Zentaris Inc announced that preclinical data for the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LH-RH) analog, AEZS-108 (formerly AN-152), in urinary bladder cancer, have been published in the online edition of Oncotarget. The article outlines AEZS-108's powerful growth inhibition of bladder cancers in nude mice, as well as its safety profile. The study investigated the expression of LH-RH receptors in clinical bladder cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect of AEZS-108 on growth of these tumor lines xenografted into nude mice was analyzed. Molecular and functional assays were used to also evaluate differences between the effects of AEZS-108 and doxorubicin (DOX), the cytotoxic moiety of AEZS-108, alone. The study demonstrated the expression of LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western blotting and binding assays. AEZS-108 powerfully inhibited growth of these bladder cancers in nude mice, exerted greater effects than DOX and was less toxic. In contrast to DOX alone which activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, AEZS-108 had no or less such effects. PCR assays and in vitro studies revealed differences in the action of AEZS-108 and DOX on the expression of genes involved in apoptosis. 

Company Quote

1.23
-0.02 -1.60%
10 Jul 2014